Oliver Ebert
Technische Universität München
40 Papers
278 Citations
Oliver Ebert is an academic researcher from Technische Universität München. The author has contributed to research in topics: Oncolytic virus & Vesicular stomatitis virus. The author has an hindex of 21, co-authored 40 publications. Previous affiliations of Oliver Ebert include University of Bonn & Icahn School of Medicine at Mount Sinai.
Chat about Author
Papers
Syncytia Induction Enhances the Oncolytic Potential of Vesicular Stomatitis Virus in Virotherapy for Cancer
Oliver Ebert,Katsunori Shinozaki,Chryssanthi Kournioti,Man Seong Park,Adolfo García-Sastre,Savio L. C. Woo +5 more
TL;DR: The construction of a recombinant VSV capable of inducing syncytia formation between tumor cells through membrane fusion at neutral pH, which led to enhanced oncolytic properties against multifocal hepatocellular carcinoma (HCC) in the livers of immunocompetent rats is reported.
120
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa,Ghassan K. Abou-Alfa,Oscar Puig,Bruno Daniele,Masatoshi Kudo,Philippe Merle,Joong-Won Park,Paul Ross,Jean-Marie Péron,Oliver Ebert,Stephen L. Chan,Tung Ping Poon,Massimo Colombo,Takuji Okusaka,Baek Yeol Ryoo,Beatriz Minguez,Takayoshi Tanaka,Toshihiko Ohtomo,Stacey Ukrainskyj,Frederic Boisserie,Olga Rutman,Ya Chi Chen,Chao Xu,Eliezer Shochat,Lori Jukofsky,Bernhard Reis,Gong Chen,Laura Di Laurenzio,Ray Lee,Chia Jui Yen +29 more
TL;DR: It was suggested though that a higher dose of codrituzumab or selecting patients with high level of glypican-3 or its mediator CD16 might improve outcome, as well as the use of CD16 and GPC3 as potential biomarkers would improve outcome.
109
Pseudotyping Vesicular Stomatitis Virus with Lymphocytic Choriomeningitis Virus Glycoproteins Enhances Infectivity for Glioma Cells and Minimizes Neurotropism
Alexander Muik,Inna Kneiske,Marina Werbizki,Doris Wilflingseder,Tsanan Giroglou,Oliver Ebert,Anna Kraft,Ursula Dietrich,Gert Zimmer,Stefan Momma,Dorothee von Laer +10 more
TL;DR: Compared to VSV, VSV-GP showed enhanced infectivity for brain cancer cells in vitro while sparing primary human and rat neurons in vitro and in vivo, respectively, and is thus more suitable for clinical applications, especially in the brain.
92
rVSV(MΔ51)-M3 Is an Effective and Safe Oncolytic Virus for Cancer Therapy
Lan Wu,Tian-Gui Huang,Marcia Meseck,Jennifer Altomonte,Oliver Ebert,Katsunori Shinozaki,Adolfo García-Sastre,John T. Fallon,John Mandeli,Savio L. C. Woo +9 more
TL;DR: The results indicate that the robust cellular inflammatory responses induced by VSV in HCC lesions can be overcome by vector-mediated intratumoral M3 expression, and that rVSV(M Delta 51)-M3 can be developed as an effective and safe oncolytic agent to treat advanced HCC patients in the future.
77
Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells.
Jennifer Altomonte,Lan Wu,Marcia Meseck,Li Chen,Oliver Ebert,Oliver Ebert,Adolfo García-Sastre,John T. Fallon,John Mandeli,Savio L. C. Woo +9 more
TL;DR: The present study suggests the applicability of this recombinant virus, rVSV-UL141, which expresses a protein from human cytomegalovirus known to downregulate the natural killer cell-activating ligand CD155, for the development of effective and safe oncolytic agents to treat multi-focal HCC, and potentially a multitude of other cancers, in the future.
76